Tel-eVax targets Telomerase, the enzyme that maintains telomeres and prevents them from shortening during cell division. Telomerase is upregulated in many tumor cells, which enables the continued and uncontrolled proliferation of the malignant cells that drive tumor growth and progression.
Tel-eVax has shown efficacy for canine B-cell Lymphoma in three trials and is currently being evaluated in other tumor types
Erb-eVax targets HER2/neu, a well validated oncogene. HER2/neu is overexpressed in Breast Cancer, Osteosarcoma, Transitional cell carcinoma and many other tumor types.
Erb-eVax induces killer T cells, antibodies and innate immunity, thus contributing to stabilizing tumor progression.